Company registration number 07027908 (England and Wales)
TRI-PHARMA LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2025
TRI-PHARMA LIMITED
COMPANY INFORMATION
Directors
Mr Harinder Johal
Mr Sanjiv Saini
Mr Gulrajwant Singh
Company number
07027908
Registered office
Alexander House
60-61 Tenby Street North
Birmingham
West Midlands
B1 3EG
Auditor
Fields Business Advisors Limited
91 Birmingham Road
West Bromwich
West Midlands
B70 6PX
TRI-PHARMA LIMITED
CONTENTS
Page
Strategic report
1
Directors' report
2
Directors' responsibilities statement
3
Independent auditor's report
4 - 5
Profit and loss account
6
Balance sheet
7
Statement of changes in equity
8
Statement of cash flows
9
Notes to the financial statements
10 - 21
TRI-PHARMA LIMITED
STRATEGIC REPORT
FOR THE YEAR ENDED 30 SEPTEMBER 2025
- 1 -
The directors present the strategic report for the year ended 30 September 2025.
Principal activities
The principal activity of the company continued to be that of dispensing chemists.
Review of the business
During the financial year ended 30 September 2025 turnover decreased by 7% to £12.5 million. The decrease in turnover is due to sale of one of branch during the year. The operating profit of the company has increased from £431K to of £1.4million. The increase is because of receiving sales proceeds of selling a branch. The board believes that the company is well positioned to continue to deliver significant operating profits and positive cash flows in the future. However, the directors anticipate the business environment will remain competitive. They believe that the company is in a good financial position and they remain confident that the company will continue to grow.
Principal risks and uncertainties
The process of risk acceptance and risk management is addressed through a framework of policies, procedures and internal controls. All policies are subject to Board approval and ongoing review by management.
Compliance with regulation, legal, and ethical standards is a high priority for the company, and the company finance department takes on an important oversight role in this regard. The top management together with finance team is responsible for satisfying itself that a proper internal control framework exists to manage financial risk, and that controls operate effectively.
Continuity of Supplies
It is important to the company that it has reliable sources of materials of the required quality at competitive prices. The company manages the risk of not being able to achieve the above objectives by identifying and building relationships, over a number of years, with a small number of reliable suppliers from whom it buys the majority of its materials. The company also sources materials from new suppliers in a more limited capacity. This allows the Board to build new relationships, gauge reliability and utilise alternative sourcing if required.
Key performance indicators
The directors consider the company's turnover and gross profit margin to be the key performance indicators which they use to manage the business.
Development and performance
The company has continued to be operating well during the financial year and all indicators show this will continue into the next financial year.
The company has paid back loan in full to reduce its long-term liabilities.
Mr Harinder Johal
Director
29 October 2026
TRI-PHARMA LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 30 SEPTEMBER 2025
- 2 -
The directors present their annual report and financial statements for the year ended 30 September 2025.
Dividends
No ordinary dividends were paid. The directors do not recommend payment of a final dividend.
Directors
The directors who held office during the year and up to the date of signature of the financial statements were as follows:
Mr Harinder Johal
Mr Sanjiv Saini
Mr Gulrajwant Singh
GOING CONCERN
The directors have considered the financial position of the company which shows healthy reserves and cash balances. They have not identified any material uncertainties that may cast significant doubt over the ability of the company to continue as a going concern for the foreseeable future, which is deemed to be at least 12 months from the date of signing these accounts. In forming their opinion, they have considered current and anticipated turnover, profit and cashflows. Going concern is presumed in preparing these financial statements.
Strategic report
The company has chosen in accordance with Companies Act 2006, s. 414C(11) to set out in the company's strategic report information required by Large and Medium-sized Companies and Groups (Accounts and Reports) Regulations 2008, Sch. 7 to be contained in the directors' report.
Statement of disclosure to auditor
So far as each person who was a director at the date of approving this report is aware, there is no relevant audit
information of which the company’s auditor is unaware. Additionally, the directors individually have taken all the
necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit
information and to establish that the company’s auditor is aware of that information.
On behalf of the board
Mr Harinder Johal
Director
29 October 2026
TRI-PHARMA LIMITED
DIRECTORS' RESPONSIBILITIES STATEMENT
FOR THE YEAR ENDED 30 SEPTEMBER 2025
- 3 -
The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.
Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period.
In preparing these financial statements, the directors are required to:
select suitable accounting policies and then apply them consistently;
make judgements and accounting estimates that are reasonable and prudent; and
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.
The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
TRI-PHARMA LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF TRI-PHARMA LIMITED
- 4 -
Opinion
We have audited the financial statements of Tri-Pharma Limited (the 'company') for the year ended 30 September 2025 which comprise the profit and loss account, the balance sheet, the statement of changes in equity, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).
In our opinion the financial statements:
give a true and fair view of the state of the company's affairs as at 30 September 2025 and of its profit for the year then ended;
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
have been prepared in accordance with the requirements of the Companies Act 2006.
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.
The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.
We have nothing to report in this regard.
TRI-PHARMA LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF TRI-PHARMA LIMITED (CONTINUED)
- 5 -
Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of our audit:
the information given in the strategic report and the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
the strategic report and the directors' report have been prepared in accordance with applicable legal requirements.
Matters on which we are required to report by exception
In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report.
We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:
adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
the financial statements are not in agreement with the accounting records and returns; or
certain disclosures of directors' remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit.
Responsibilities of directors
As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.
Auditor's responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.
Mrs Stella Louise Broomhall FCCA (Senior Statutory Auditor)
For and on behalf of Fields Business Advisors Limited, Statutory Auditor
Chartered Certified Accountants
91 Birmingham Road
West Bromwich
West Midlands
B70 6PX
30 October 2026
TRI-PHARMA LIMITED
PROFIT AND LOSS ACCOUNT
FOR THE YEAR ENDED 30 SEPTEMBER 2025
- 6 -
Year
Year
ended
ended
30 September
30 September
2025
2024
Notes
£
£
Gross profit
3,571,758
4,008,706
Administrative expenses
(2,119,132)
(3,577,125)
Operating profit
3
1,452,626
431,581
Interest payable and similar expenses
(41,431)
(17,095)
Profit before taxation
1,411,195
414,486
Tax on profit
6
(129,699)
(193,394)
Profit for the financial year
1,281,496
221,092
The profit and loss account has been prepared on the basis that all operations are continuing operations.
TRI-PHARMA LIMITED
BALANCE SHEET
AS AT 30 SEPTEMBER 2025
30 September 2025
- 7 -
2025
2024
Notes
£
£
£
£
Fixed assets
Goodwill
7
383,031
694,518
Tangible assets
8
1,252,421
1,343,030
Investments
9
240
1,635,692
2,037,548
Current assets
Stocks
10
631,057
762,402
Debtors
11
2,659,164
3,135,290
Cash at bank and in hand
858,658
1,017,596
4,148,879
4,915,288
Creditors: amounts falling due within one year
12
(2,502,263)
(4,228,274)
Net current assets
1,646,616
687,014
Total assets less current liabilities
3,282,308
2,724,562
Creditors: amounts falling due after more than one year
13
(700,605)
Provisions for liabilities
Deferred tax liability
14
90,495
113,640
(90,495)
(113,640)
Net assets
3,191,813
1,910,317
Capital and reserves
Called up share capital
15
300
300
Profit and loss reserves
3,191,513
1,910,017
Total equity
3,191,813
1,910,317
These financial statements have been prepared in accordance with the provisions relating to medium-sized companies.
The financial statements were approved by the board of directors and authorised for issue on 29 October 2026 and are signed on its behalf by:
Mr Harinder Johal
Director
Company registration number 07027908 (England and Wales)
TRI-PHARMA LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 SEPTEMBER 2025
- 8 -
Share capital
Profit and loss reserves
Total
£
£
£
Balance at 1 October 2023
300
1,688,925
1,689,225
Period ended 30 September 2024:
Profit and total comprehensive income
-
221,092
221,092
Balance at 30 September 2024
300
1,910,017
1,910,317
Period ended 30 September 2025:
Profit and total comprehensive income
-
1,281,496
1,281,496
Balance at 30 September 2025
300
3,191,513
3,191,813
TRI-PHARMA LIMITED
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 30 SEPTEMBER 2025
- 9 -
Year ended
Year ended
30 September 2025
30 September 2024
Notes
£
£
£
£
Cash flows from operating activities
Cash (absorbed by)/generated from operations
18
(399,544)
103,247
Interest paid
(41,431)
(17,095)
Income taxes paid
(121,748)
(189,291)
Net cash outflow from operating activities
(562,723)
(103,139)
Investing activities
Proceeds from disposal of intangibles
1,200,000
Purchase of tangible fixed assets
(32,190)
(1,193,919)
Proceeds from disposal of tangible fixed assets
4,217
Proceeds from disposal of subsidiaries
(240)
Net cash generated from/(used in) investing activities
1,171,787
(1,193,919)
Financing activities
Repayment of borrowings
55
(723)
Repayment of bank loans
(730,627)
730,627
Net cash (used in)/generated from financing activities
(730,572)
729,904
Net decrease in cash and cash equivalents
(121,508)
(567,154)
Cash and cash equivalents at beginning of year
980,166
1,547,320
Cash and cash equivalents at end of year
858,658
980,166
Relating to:
Cash at bank and in hand
858,658
1,017,596
Bank overdrafts included in creditors payable within one year
(37,430)
TRI-PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2025
- 10 -
1
Accounting policies
Company information
Tri-Pharma Limited is a private company limited by shares incorporated in England and Wales. The registered office is Alexander House, 60-61 Tenby Street North, Birmingham, West Midlands, B1 3EG.
1.1
Basis of preparation
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £1.
The financial statements have been prepared under the historical cost convention. The principal accounting
policies adopted are set out below.
1.2
Going concern
Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.
1.3
Revenue
Revenue comprises sales of goods or services provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts. Revenue is recognised when performance obligations are satisfied and the control of goods or services is transferred to the buyer. Where the performance obligation is satisfied over time, revenue is recognised in accordance with its progress towards complete satisfaction of that performance obligation.
When cash inflows are deferred and represent a financing arrangement, the promised consideration is adjusted for the effects of the time value of money, which is recognised as interest income.
The nature, timing of satisfaction of performance obligations and significant payment terms of the company's major sources of revenue are as follows:
Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.
Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that are recoverable.
TRI-PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
1
Accounting policies
(Continued)
- 11 -
1.4
Intangible fixed assets - goodwill
Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 10 years.
For the purposes of impairment testing, goodwill is allocated to the cash-generating units expected to benefit from the acquisition. Cash-generating units to which goodwill has been allocated are tested for impairment at least annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit.
1.5
Tangible fixed assets
Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Land and buildings Freehold
NIL
Plant and machinery
20% on a reducing balance
Fixtures, fittings & equipment
20% on a reducing balance
Motor vehicles
25% on a reducing balance
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.
1.6
Fixed asset investments
Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.
A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.
An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a long-term interest and where the company has significant influence. The company considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.
Entities in which the company has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities.
1.7
Impairment of fixed assets
At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.
TRI-PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
1
Accounting policies
(Continued)
- 12 -
Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted. If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.
Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.
1.8
Stocks
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.
Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.
At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.
1.9
Cash and cash equivalents
Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.
1.10
Financial instruments
The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.
Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.
TRI-PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
1
Accounting policies
(Continued)
- 13 -
Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
Basic financial liabilities
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
1.11
Equity instruments
Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.
1.12
Derivatives
Derivatives are initially recognised at fair value at the date a derivative contract is entered into and are subsequently remeasured to fair value at each reporting end date. The resulting gain or loss is recognised in profit or loss immediately unless the derivative is designated and effective as a hedging instrument, in which event the timing of the recognition in profit or loss depends on the nature of the hedge relationship.
A derivative with a positive fair value is recognised as a financial asset, whereas a derivative with a negative fair value is recognised as a financial liability.
1.13
Taxation
The tax expense represents the sum of the tax currently payable and deferred tax.
Current tax
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
TRI-PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
1
Accounting policies
(Continued)
- 14 -
Deferred tax
Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.
The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.
The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.
1.14
Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.
The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.
Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.
1.15
Retirement benefits
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.
1.16
Leases
As lessor
When the company acts as a lessor, a lease is classified as a finance lease whenever it transfers substantially all the risks and rewards of ownership of the underlying asset to the lessee, either at the end of the lease term or for the major part of the economic life of the asset. All other leases are classified as operating leases. If an arrangement contains both lease and non-lease components, the company allocates the consideration in the contract to the two elements.
Rental income from operating leases is recognised on a straight line basis over the term of the relevant lease. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognised on a straight line basis over the lease term.
TRI-PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
1
Accounting policies
(Continued)
- 15 -
1.17
Government grants
Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.
A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.
1.18
Foreign exchange
Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.
2
Judgements and key sources of estimation uncertainty
In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.
3
Operating profit
2025
2024
Operating profit for the period is stated after charging/(crediting):
£
£
Government grants
(397)
(500)
Fees payable to the company's auditor for the audit of the company's financial statements
23,000
Accountancy
21,542
20,997
Depreciation of tangible fixed assets
101,861
85,447
Loss on disposal of tangible fixed assets
16,720
-
Amortisation of intangible assets
311,487
380,387
Profit on disposal of intangible assets
(1,200,000)
-
4
Employees
The average monthly number of persons (including directors) employed by the company during the year was:
2025
2024
Number
Number
86
92
TRI-PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
4
Employees
(Continued)
- 16 -
Their aggregate remuneration comprised:
2025
2024
£
£
Wages and salaries
1,671,814
1,696,723
Social security costs
129,923
98,604
Pension costs
194,460
194,887
1,996,197
1,990,214
5
Directors' remuneration
2025
2024
£
£
Remuneration for qualifying services
36,000
36,000
Company pension contributions to defined contribution schemes
180,000
180,000
216,000
216,000
6
Taxation
2025
2024
£
£
Current tax
UK corporation tax on profits for the current period
152,845
117,705
Deferred tax
Origination and reversal of timing differences
(23,146)
75,689
Total tax charge
129,699
193,394
TRI-PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
6
Taxation
(Continued)
- 17 -
The actual charge for the year can be reconciled to the expected charge for the year based on the profit or loss and the standard rate of tax as follows:
2025
2024
£
£
Profit before taxation
1,411,195
414,486
Expected tax charge based on the standard rate of corporation tax in the UK of 25% (2024: 25%)
352,799
103,622
Effects of:
Expenses that are not deductible in determining taxable profit
103,337
99,235
Gains not taxable
(300,000)
loss on disposal of fixed assets
4,180
Deferred tax
(23,146)
75,689
Capital allowance
(7,471)
(85,152)
Taxation charge in the financial statements
129,699
193,394
7
Intangible fixed assets
Goodwill
£
Cost
At 1 October 2024
4,050,567
Disposals
(688,997)
At 30 September 2025
3,361,570
Amortisation and impairment
At 1 October 2024
3,356,049
Amortisation charged for the year
311,487
Amortisation eliminated on disposals
(688,997)
At 30 September 2025
2,978,539
Carrying amount
At 30 September 2025
383,031
At 30 September 2024
694,518
TRI-PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
- 18 -
8
Tangible fixed assets
Land and buildings Freehold
Plant and machinery
Fixtures, fittings & equipment
Motor vehicles
Total
£
£
£
£
£
Cost
At 1 October 2024
857,832
275,890
588,660
198,429
1,920,812
Additions
25,690
6,500
32,190
Disposals
(44,751)
(56,330)
(101,081)
At 30 September 2025
857,832
275,890
569,600
148,599
1,851,921
Depreciation and impairment
At 1 October 2024
22,683
436,792
118,307
577,782
Depreciation charged in the year
50,641
33,747
17,473
101,861
Eliminated in respect of disposals
(35,928)
(44,214)
(80,142)
At 30 September 2025
73,324
434,610
91,566
599,500
Carrying amount
At 30 September 2025
857,832
202,566
134,990
57,033
1,252,421
At 30 September 2024
857,832
253,207
151,870
80,121
1,343,030
9
Fixed asset investments
2025
2024
Notes
£
£
Investments in subsidiaries
240
Movements in fixed asset investments
Shares in subsidiaries
£
Cost or valuation
At 1 October 2024
-
Additions
240
At 30 September 2025
240
Carrying amount
At 30 September 2025
240
At 30 September 2024
-
TRI-PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
- 19 -
10
Stocks
2025
2024
£
£
Finished goods and goods for resale
631,057
762,402
11
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
1,606,194
1,990,861
Other debtors
986,756
1,056,259
Prepayments and accrued income
66,214
88,170
2,659,164
3,135,290
Other debtors include a balance of £684,373 (2024: £nil ) due from the related company Delta Healthcare Services Ltd and £73,000 (2024: nil) from MV Horizon Group Limited.
12
Creditors: amounts falling due within one year
2025
2024
Notes
£
£
Bank loans and overdrafts
67,452
Other borrowings
2,987
2,932
Trade creditors
1,578,731
2,509,286
Corporation tax
152,845
121,749
Other taxation and social security
23,559
19,218
Other creditors
47,142
746,506
Accruals and deferred income
696,999
761,131
2,502,263
4,228,274
Included in other creditors is an amount of £47,142 (2024: £21,439 ) owed to the directors. This amount is interest free and without a fixed repayment period.
13
Creditors: amounts falling due after more than one year
2025
2024
Notes
£
£
Bank loans and overdrafts
700,605
TRI-PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
- 20 -
14
Deferred taxation
Deferred tax assets and liabilities are offset where the company has a legally enforceable right to do so. The following is the analysis of the deferred tax balances (after offset) for financial reporting purposes:
Liabilities
Liabilities
2025
2024
Balances:
£
£
Deferred Tax
113,640
113,640
Movement during the year
(23,145)
-
90,495
113,640
15
Share capital
2025
2024
Ordinary share capital
£
£
Issued and fully paid
300 Ordinary shares of £1 each
300
300
16
Related party transactions
Transactions with related parties
During the year the company entered into the following transactions with related parties:
Tri-Pharma Limited is due £684,373 (2024: £nil) from its subsidiary Delta Healthcare Services Ltd and £73,000 (2024: £nil) from MV Horizon Group Ltd in which directors of Tri-Pharma Limited are also the directors.
This loan is interest free and without a fixed capital repayment period.
Management charges of £222,130 have been charged to the company by directors' associated companies.
17
Ultimate controlling party
The company is controlled by the directors Mr Harinder Johal, Mr Sanjiv Saini and Mr Gulrajwant Singh .
TRI-PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
- 21 -
18
Cash (absorbed by)/generated from operations
2025
2024
£
£
Profit after taxation
1,281,496
221,092
Adjustments for:
Taxation charged
129,699
193,394
Finance costs
41,431
17,095
Loss on disposal of tangible fixed assets
16,720
-
Gain on disposal of intangible assets
(1,200,000)
-
Amortisation and impairment of intangible assets
311,487
380,387
Depreciation and impairment of tangible fixed assets
101,861
85,447
Movements in working capital:
Decrease/(increase) in stocks
131,346
(46,433)
Decrease/(increase) in debtors
476,126
(870,335)
(Decrease)/increase in creditors
(1,689,710)
122,600
Cash (absorbed by)/generated from operations
(399,544)
103,247
19
Analysis of changes in net funds
1 October 2024
Cash flows
30 September 2025
£
£
£
Cash at bank and in hand
1,017,596
(158,938)
858,658
Bank overdrafts
(37,430)
37,430
980,166
(121,508)
858,658
Borrowings excluding overdrafts
(733,559)
730,572
(2,987)
246,607
609,064
855,671
2025-09-302024-10-01falsefalsefalseCCH SoftwareCCH Accounts Production 2026.210Mr Harinder JohalMr Sanjiv SainiMr Gulrajwant Singh070279082024-10-012025-09-3007027908bus:Director12024-10-012025-09-3007027908bus:Director22024-10-012025-09-3007027908bus:Director32024-10-012025-09-3007027908bus:RegisteredOffice2024-10-012025-09-30070279082025-09-30070279082023-10-012024-09-3007027908core:RetainedEarningsAccumulatedLosses2023-10-012024-09-3007027908core:RetainedEarningsAccumulatedLosses2024-10-012025-09-3007027908core:Goodwill2025-09-3007027908core:Goodwill2024-09-30070279082024-09-3007027908core:LandBuildingscore:OwnedOrFreeholdAssets2025-09-3007027908core:PlantMachinery2025-09-3007027908core:FurnitureFittings2025-09-3007027908core:MotorVehicles2025-09-3007027908core:LandBuildingscore:OwnedOrFreeholdAssets2024-09-3007027908core:PlantMachinery2024-09-3007027908core:FurnitureFittings2024-09-3007027908core:MotorVehicles2024-09-3007027908core:WithinOneYear2025-09-3007027908core:WithinOneYear2024-09-3007027908core:CurrentFinancialInstrumentscore:WithinOneYear2025-09-3007027908core:CurrentFinancialInstrumentscore:WithinOneYear2024-09-3007027908core:Non-currentFinancialInstrumentscore:AfterOneYear2025-09-3007027908core:Non-currentFinancialInstrumentscore:AfterOneYear2024-09-3007027908core:ShareCapital2025-09-3007027908core:ShareCapital2024-09-3007027908core:RetainedEarningsAccumulatedLosses2025-09-3007027908core:RetainedEarningsAccumulatedLosses2024-09-3007027908core:ShareCapital2023-09-3007027908core:RetainedEarningsAccumulatedLosses2023-09-3007027908core:ShareCapitalOrdinaryShareClass12025-09-3007027908core:ShareCapitalOrdinaryShareClass12024-09-300702790812024-10-012025-09-300702790812023-10-012024-09-30070279082024-09-30070279082023-09-3007027908core:Goodwill2024-10-012025-09-3007027908core:LandBuildingscore:OwnedOrFreeholdAssets2024-10-012025-09-3007027908core:PlantMachinery2024-10-012025-09-3007027908core:FurnitureFittings2024-10-012025-09-3007027908core:MotorVehicles2024-10-012025-09-3007027908core:UKTax2024-10-012025-09-3007027908core:UKTax2023-10-012024-09-300702790822024-10-012025-09-300702790822023-10-012024-09-300702790832024-10-012025-09-300702790832023-10-012024-09-300702790842024-10-012025-09-300702790842023-10-012024-09-3007027908core:Goodwill2024-09-3007027908core:LandBuildingscore:OwnedOrFreeholdAssets2024-09-3007027908core:PlantMachinery2024-09-3007027908core:MotorVehicles2024-09-3007027908core:Non-currentFinancialInstruments2025-09-3007027908core:Non-currentFinancialInstruments2024-09-3007027908core:CurrentFinancialInstruments2025-09-3007027908core:CurrentFinancialInstruments2024-09-3007027908bus:OrdinaryShareClass12024-10-012025-09-3007027908bus:PrivateLimitedCompanyLtd2024-10-012025-09-3007027908bus:FRS1022024-10-012025-09-3007027908bus:Audited2024-10-012025-09-3007027908bus:FullAccounts2024-10-012025-09-30xbrli:purexbrli:sharesiso4217:GBP